Your morning prescription might be a national security vulnerability. That is the blunt warning issued today by the leadership of the U.S. Senate Special Committee on Aging, which released new findings detailing the United States’ deepening reliance on generic medications manufactured in China and India.
Committee Chairman Sen. Rick Scott (R-Fla.) issued a formal warning to aging Americans regarding the stability and safety of the nation’s drug supply chain. The alert follows a months-long bipartisan investigation led by Scott and Ranking Member Sen. Kirsten Gillibrand (D-N.Y.) that characterizes the current pharmaceutical landscape as a “dangerous overreliance” on foreign entities.
READ: U.S. Doors Close For 20 More Nations In Major Security Overhaul
“Every American relying on foreign-manufactured generic drugs deserves to know the risks in their medicine cabinet,” Scott said in a statement accompanying the report.
The committee’s investigation highlights a dramatic shift in where Americans get their medicine. According to the data released Tuesday, the U.S. manufactured 83% of its consumed pharmaceuticals in 2002. By 2024, that figure had plummeted to just 37%.
The report suggests that this supply chain shift has left the U.S. vulnerable to quality control issues and potential geopolitical leverage. Currently, roughly 80% of the active pharmaceutical ingredients (APIs) used in drugs consumed by Americans originate in India or China.
Specific common medications are almost entirely dependent on foreign supply lines. The report notes that China now accounts for 95% of U.S. ibuprofen imports, 70% of acetaminophen imports, and more than 45% of penicillin imports.
READ: ‘It’s All Bullsh*t’: Minnesota Gov. Walz Lashes Out At Gun Owners While $1B Fraud Scandal Looms
Scott framed the issue as a dual threat: public health and national security. He argued that the Chinese Communist Party holds the ability to “cut off the supply at any moment,” which would leave seniors and military personnel without essential treatments.
Beyond the supply chain logistics, the committee raised concerns regarding safety standards. The investigation pointed to a disparity in regulatory oversight, noting that the FDA conducts fewer unannounced inspections of foreign facilities compared to domestic ones.
The committee cited a 2025 study indicating that serious adverse health events—including hospitalization and death—were 54% higher for generic drugs manufactured in India compared to equivalent drugs made in the United States.
“Americans should not be forced to roll the dice with the safety, supply, or availability of their medicine,” Scott said. “This is a threat to our national security and personal safety that must change.”
READ: Vance Shrugs Off Chief Of Staff’s ‘Conspiracy Theorist’ Dig: ‘I Only Believe The True Ones’
In response to the findings, the committee leadership has sent letters to key health officials, including incoming Department of Health and Human Services Secretary Robert F. Kennedy, Jr., FDA Commissioner Martin Makary, and VA Secretary Doug Collins.
The committee outlined several legislative and regulatory solutions to reverse the trend. Recommendations include establishing a “federal buyer’s market” that prioritizes American-made medicines, requiring clear “country of origin” labeling on prescription bottles, and closing legal loopholes that allow foreign products to be categorized as “Made in America.”
Chairman Scott emphasized that the goal is to expand domestic biotechnology and ensure that when American families open their medicine cabinets, they can trust what they find inside.
Please make a small donation to the Tampa Free Press to help sustain independent journalism. Your contribution enables us to continue delivering high-quality, local, and national news coverage.
Sign up: Subscribe to our free newsletter for a curated selection of top stories delivered straight to your inbox.
